Are Silver Nanoparticles Useful for Treating Second-Degree Burns? An Experimental Study in Rats.

Journal: Advanced pharmaceutical bulletin
Published Date:

Abstract

In this work, the potential usefulness of silver nanoparticles (AgNPs) for treating burn wounds was examined. Second-degree burns were induced in male Wistar rats by touching the skin with a heated (70°C) metallic device for 10 s, after which the animals were randomly allocated to one of two groups: control (n=8, treated with sterile saline) and experimental (n=8, treated with AgNPs, 0.081 mg/mL; 50 µL applied to the burn surface). Seven, 14, 21 and 28 days after lesion induction two rats from each group were killed and blood samples were collected for a complete blood count and to assess oxidative stress. The livers were examined macroscopically and skin samples were collected for histological analysis. Macroscopically, wound healing and skin remodeling in the experimental group were similar to the saline-treated rats. Likewise, there were no significant differences in the histological parameters between the two groups. However, treatment with AgNPs caused a persistent reduction in white blood cell (WBC) counts throughout the experiment, whereas platelet counts increased on days 7 and 28 but decreased on days 14 and 21; there was also an increase in the blood concentration of reduced glutathione on day 7 followed by a decrease on days 21 and 28. There were no significant changes in blood glutathione peroxidase (GSH-Px) and catalase (CAT) activities or in the serum concentration of thiobarbituric acid reactive substances. The findings of this study raise questions about the potential transitory effects of AgNPs based on the changes in WBC and platelet counts, blood glutathione concentrations and macroscopic hepatic alterations.

Authors

  • Débora Antunes Neto Moreno
    Graduate Program in Pharmaceutical Sciences, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Mirela Santos Saladini
    Veterinary Medicine Graduate Course, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Fabia Judice Marques Viroel
    Graduate Program in Pharmaceutical Sciences, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Murilo Melo Juste Dini
    Graduate Program in Pharmaceutical Sciences, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Thaisa Borim Pickler
    Laboratory for Toxicological Research (Lapetox), University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Jorge Amaral Filho
    Veterinary Medicine Graduate Course, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Carolina Alves Dos Santos
    Graduate Program in Pharmaceutical Sciences, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Valquíria Miwa Hanai-Yoshida
    Graduate Program in Environmental and Technological Processes, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Denise Grotto
    Graduate Program in Pharmaceutical Sciences, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.
  • Marli Gerenutti
    School of Medical Sciences of the Pontifical Catholic University of São Paulo (PUC-SP), Sorocaba, SP, Brazil.
  • Stephen Hyslop
    Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil.
  • Yoko Oshima-Franco
    Graduate Program in Pharmaceutical Sciences, University of Sorocaba (UNISO), Sorocaba, SP, Brazil.

Keywords

No keywords available for this article.